

JAMES C. LAI

Addresses

Work:
Retina Consultants of Hawaii
98-1079 Moanalua Road, Suite 470
Aiea, Hawaii 96701
808-487-8928

Retina Consultants of Hawaii
321 N. Kuakini Street, Suite 307
Honolulu, HI 96817
808-523-6131

Retina Consultants of Hawaii
1380 Lusitana Street, Suite 506
Honolulu, HI 96813
808-545-7045

The Retina Center at Pali Momi
98-1079 Moanalua Road, Suite 470
Aiea, Hawaii 96701
808-487-8928

Education

2002- 2003

Chief Resident, Assistant Chief of Service,
and Director of Ocular Trauma Service
Wilmer Ophthalmological Institute
Johns Hopkins Medical Institutions
Baltimore, MD

2000-2002

Vitreoretinal Fellowship
Duke University Eye Center
Durham, NC

1997-2000

Ophthalmology Residency Program
The Wilmer Ophthalmological Institute
Johns Hopkins Medical Institutions
Baltimore, MD

1996-1997

University of Hawaii Integrated Transitional Residency Program
Honolulu, HI

1991-1996

Doctor of Medicine
University of Michigan Medical School
Ann Arbor, MI

- Top 5 of the class
- Dean's Award for Research Excellence
- Graduated with Distinction in Research

1993-1994 Howard Hughes Medical Institute-National Institutes of Health (HHMI-NIH) Research Scholars Program
• Laboratory of Immunology at the National Eye Institute, NIH
• Preceptors: Drs. Igal Gery and Robert Nussenblatt

1988-1992 Bachelor of Science in Biomedical Sciences
University of Michigan, Ann Arbor, MI
• 7-year Integrated Premedical-Medical (Inteflex) Program
• GPA: 3.93/4.00, Graduated Summa Cum Laude

Board Certification American Board of Ophthalmology
October 28, 2001

Licensure Hawaii 14115 (active)
New York- 227432 (inactive)
Maryland- D0058707 (inactive)
North Carolina- 2000 00249 (inactive)
DEA- BL6695879

Professional Activities

2003-May 2007 Long Island and Queens Vitreoretinal Consultants
600 Northern Blvd., Suite 216
Great Neck, NY 11021

May 2007 – present Retina Consultants of Hawaii
98-1079 Moanalua Road, Suite 470
Aiea, Hawaii 96701

Retina Consultants of Hawaii
321 North Kuakini Street, Suite 307
Honolulu, HI 96817

The Retina Center at Pali Momi
98-1079 Moanalua Road, Suite 470
Aiea, Hawaii 96701

June 2008- April 2011 Retina Consultants of Hawaii
1380 Lusitana Street, Suite 502
Honolulu, HI 96813

April 2011 – present Retina Consultants of Hawaii
1380 Lusitana Street, Suite 506
Honolulu, HI 96813

Hospital Appointments:

7/03-2007 North Shore University Hospital at Syosset, Syosset, NY
7/03-2007 Queens Hospital Center, Jamaica, NY

8/03-2007 Long Island Jewish Hillside Medical Center, New Hyde Park, NY
5/07-present Pali Momi Medical Center, Aiea, HI
5/07-present Queens Medical Center, Honolulu, HI

Academic Positions

2009 – present Clinical Assistant Professor
Department of Surgery
John A Burns School of Medicine, University of Hawaii

2006-2007 Clinical Assistant Professor
Department of Ophthalmology
NYU School of Medicine

2003-2007 Attending Surgeon
Department of Ophthalmology
Long Island Jewish/North Shore University

2002- 2003 Assistant Chief of Service and
Director of Ocular Trauma Service
Wilmer Ophthalmological Institute
Johns Hopkins Medical Institutions

2000- 2002 Clinical Instructor
Retina Division
Duke University Eye Center

Honors and Awards

2009 – present Best Doctors in America

2005-2006 Teaching Attending of Year
Long Island Jewish/North Shore University
Department of Ophthalmology

2002 Hornaday Fellow Teaching Award
Duke University Eye Center

2000 Awarded AOS-Knapp Ophthalmic Foundation Fellowship

2000 Selected as Ronald G. Michels Foundation Award recipient

2000 Selected as the Society of Heed Fellows Fellow
(awarded to the top Heed Fellow in the nation)

2000 Awarded Heed Ophthalmic Foundation Fellowship

1999 Ronald G. Michels Resident Research Award
The Wilmer Ophthalmological Institute

1998 ARVO Travel Grant

1996	Hewlett-Packard Award Presented to the top 5 graduates of the medical school class
1996	Dean's Award for Research Excellence Awarded to the 2 graduating students who made outstanding research contributions during their medical school career.
1994	Alpha Omega Alpha (selected in junior year)
1994-1996	HHMI-NIH Research Scholars Continued Medical Studies Fellowship This scholarship, valued at \$55,200, is awarded to the top Scholars who demonstrated both outstanding research abilities and the most potential for a career in academic medicine.
1992-1996	Joseph Collins Foundation Scholarship Awarded to one student from each medical school class based on their academic performance, interests in the arts and sciences, and record of community service.
1991	Phi Beta Kappa
1991-1992	Literature, Sciences and Arts Academic Scholarship
1991-1992	University of Michigan Merit Scholarship
1991-1992	Stanley Waltz Alumni Academic Scholarship
1989-1992	Designated Angell Scholar for academic excellence
1988-1992	Class Honors
1989	William Branstrom Freshman Prize for academic excellence
1988	Westinghouse Science Talent Search, Semi-Finalist
1988	Winner in NY State Energy Conservation Research Competition
1988	National Merit Scholarship Winner
1988	High School Valedictorian (class of 525)

Publications

1. **Lai JC**, Wawrousek EF, Lee RS, Chan CC, Whitcup SM, Gery I. Intraocular inflammation in transgenic mice expressing a foreign antigen in their lens. *Ocul Immunol Inflamm.* 1995; 3:59-62.
2. **Lai JC**, Wawrousek EF, Sipe JD, Whitcup SM, Gery I. Reduced susceptibility to IL-1 and endotoxin in transgenic mice expressing IL-1 in their lens. *Cytokine.* 1996; 8(4):288-293.
3. Whitcup SM, Rizzo LV, **Lai JC**, Hayashi S, Gazzinelli R, Chan CC. IL-12 inhibits endotoxin-induced inflammation in the eye. *Eur J Immunol.* 1996; 26(5):995-999.
4. Fukushima A, **Lai JC**, Chanaud NP, Shiloach J, Whitcup SM, Nussenblatt RB, Gery I. Permissive recognition of immunodominant determinants of the retinal S-antigen in different rat strains, primates and humans. *Int Immunol.* 1997; 9(1):169-177.
5. **Lai JC**, Johnson MW, Martonyi CL, Till GO. Complement-induced retinal arteriolar occlusions in the cat. *Retina.* 1997; 81(2):499-505.

6. Whitcup SM, Pleyer U, **Lai JC**, Lutz S, Mochizuki M, Chan CC. Topical liposome-encapsulated FK-506 for the treatment of endotoxin-induced uveitis. *Ocul Immunol Inflamm.* 1998; 6(1):51-56.
7. **Lai JC**, Fukushima A, Wawrousek EF, Lobanoff MC, Charukamnoetkanok P, Smith-Gill S, Lee RS, Egwuagu CE, Whitcup SM, Gery I. Immunotolerance against a foreign antigen transgenically expressed in the lens. *Invest Ophthalmol Vis Sci.* 1998; 39(11):2049-2057.
8. Hwang JM, Girkin CA, Perry JD, **Lai JC**, Miller NR, Hellmann DB. Bilateral ocular ischemic syndrome secondary to giant cell arteritis progressing despite steroid treatment. *Am J Ophthalmol.* 1999; 127(1):102-104.
9. **Lai JC**, Lobanoff MC, Fukushima A, Wawrousek EF, Chan CC, Whitcup SM, Gery I. Uveitis induced by lymphocytes sensitized against a transgenically expressed lens protein. *Invest Ophthalmol Vis Sci.* 1999; 40(11):2735-2739.
10. de Vos AF, Fukushima A, Lobanoff MC, Vistica BP, **Lai JC**, Grivel JC, Wawrousek EF, Whitcup SM, Gery I. Breakdown of tolerance to a neo-self antigen in double transgenic mice in which B cells present the antigen. *J. Immun.* 2000;164:4594-4600.
11. Margalit E, Fujii GY, **Lai JC**, Gupta P, Chen S, Shyu J, Piyathaisere DV, Weiland JD, de Juan E, Humayun MS. Bioadhesives for intraocular use. *Retina.* 2000; 20:469-477.
12. **Lai JC**, Fekrat S, Barron Y, Goldberg MF. Traumatic hyphema in children: risk factors for complications. *Arch Ophthalmol.* 2001; 119:64-70.
13. **Lai JC**, Lapolice DJ, Stinnett SS, Meyer CH, Arieu LM, Keller MA, Toth CA. Visual outcomes following macular translocation surgery with 360° peripheral retinectomy. *Arch Ophthalmol.* 2002; 120:1317-1324
14. Stout JE, **Lai JC**, Giner J, Hamilton CD. Reactivation of retinal toxoplasmosis despite evidence of immune response to highly active antiretroviral therapy. *Clinical Infectious Diseases.* 2002; 35:37-39.
15. Greenman H, **Lai JC**. Contemporary approaches to management of hyphema. *Contemporary Ophthalmology.* 2002; 1(19):1-6.
16. **Lai JC**, Stinnett SS, McCuen BW. Comparison of silicone oil vs. gas tamponade in the treatment of idiopathic full-thickness macular hole. *Ophthalmology.* 2003; 110(6):1170-4.
17. **Lai JC**, Stinnett SS, Jaffe GJ. B-scan ultrasonography for the detection of macular thickening. *Am J Ophthalmol.* 2003; 136(1):55-61
18. **Lai JC**, Postel EA, McCuen BW. Recovery of visual function after removal of chronic subfoveal perfluorocarbon liquid. *Retina.* 2003; 23(6):868-70
19. Lai MM, **Lai JC**, Lee WH, Huang JJ, Patel S, Ying HS, Melia M, Haller JA, Handa JT. Comparison of retrobulbar and sub-Tenon's capsule injection of local anesthetic in vitreoretinal surgery. *Ophthalmology.* 2005; 112(4):574-9.

20. **Lai JC** and Shakin J. Diagnostic and therapeutic challenges. *Retina*. 2005; 25(7):930-5.
21. Mruthyunjaya P, Wirostko WJ, Chandrashekhar R, Stinnett S, **Lai JC**, Deramo V, Tang J, Dev S, Postel EA, Connor TB, Fekrat S. Central retinal vein occlusion in patients treated with long-term warfarin sodium (Coumadin) for anticoagulation. *Retina*. 2006; 26(3):285-91.
22. Deramo VA, **Lai JC**, Fastenberg DM, Udell IJ. Acute endophthalmitis in eyes treated prophylactically with fourth-generation fluoroquinolone antibiotics. *Am J Ophthalmol*. 2006; 142(5):721-5.
23. Yoganathan P, Deramo VA, **Lai JC**, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. *Retina*. 2006; 26(9):994-98.
24. Jonisch J, **Lai JC**, Deramo VA, Flug AJ and Fastenberg DM. Increase incidence of sterile endophthalmitis following intravitreal preserved Triamcinolone actinide. *Br. J. Ophthalmol*. 2008; 92: 1051-1054.
25. Shaikh S, Davis JL, Yeung L, **Lai JC**. Diagnostic and therapeutic challenges. *Retina*. 2009 Mar; 29(3):409-12.
26. Kokame GT, Yeung L, **Lai JC**. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy. *Br J Ophthal*. 2010 Mar; 94(3): 297-301. Epub 2009 Sep 1.
27. Yueng L, Kokame GT, Brod RD, Lightman DA, **Lai JC**. Pneumatic Retinopexy for retina detachment associated with severe choroidal detachment. *Retina*. 2010 Aug 13.
28. Yeung L, Kokame GT, Brod TD, Lightman DA, **Lai JC**. Pneumatic retinopexy for retinal detachment associated with severe choroidal detachment. *Retina*. 2011 Jan; 31(1): 87-92.
29. Kokame GT, Yeung L, Teramoto K, **Lai JC**, Wee R. Polypoidal choroidal vasculopathy exudation and hemorrhage – results of ranibizumab therapy at one year. *Ophthalmologica* 2013; In press.

Book Chapters

1. **Lai JC**, Wawrousek EF, Lee RS, Chan CC, Whitcup SM, Gery I. Analysis of peripheral tolerance to autologous antigens expressed in an immunologically privileged site. In: Nussenblatt RB, Whitcup SM, Caspi RR, Gery I (editors). *Advances in Ocular Immunology*. Amsterdam: Elsevier Publishers, 1994.
2. Wawrousek EF, **Lai JC**, Gery I, Chan CC. Progressive inflammatory disease and neovascularization in the eyes of interleukin-1 β transgenic mice. In: Nussenblatt RB, Whitcup SM, Caspi RR, Gery I (editors). *Advances in Ocular Immunology*. Amsterdam: Elsevier Publishers, 1994.
3. **Lai JC**, Cooney M. Photodynamic therapy. In: Dunn JP (editor). *Macular Disease*. In *International Ophthalmology Clinics*. Hagerstown: Lippincott Williams and Wilkins, 1999.

Book Reviews

1. **Lai JC.** The Massachusetts Eye and Ear Infirmary Illustrated Manual of Ophthalmology. [book review]. *Am J Ophthalmol.* 1998; 126(6):854.
2. **Lai JC.** Principles and Practice of Ophthalmology. Second Edition. Editors: Albert DM and Jakobiec FA. [book review]. *Am J Ophthalmol.* 2000; 129(5):699-700.

Selected Abstracts and Presentations

1. **JC Lai, CC Chan, Q Lian, SM Whitcup.** Treatment with corticosteroids and cyclosporine A inhibits the expression of adhesion molecules in experimental autoimmune uveitis. *Invest Ophthalmol Vis Sci.* 34 (Suppl): 1206, 1993.
2. **JC Lai, CL Martonyi, MW Johnson.** Experimental complement-induced retinal arteriolar occlusions in the cat. (Oral presentation at 1993 National Student Research Forum, Galveston, Tx)
3. **JC Lai, EF Wawrousek, JD Sipe, SM Whitcup, CC Chan, I Gery.** Ocular and systemic immunological profile of interleukin-1 β (IL-1 β) transgenic mice. *Invest Ophthalmol Vis Sci.* 35 (Suppl): 1988, 1994. (Oral presentation, 1994 ARVO meeting)
4. **RC Walton, JC Lai, NP Chanaud, CC Chan, I Gery, SM Whitcup.** Inhibition of experimental autoimmune uveitis by MDL 28,842. *Invest Ophthalmol Vis Sci.* 35 (Suppl): 1865, 1994.
5. **JC Lai, BP Vistica, RK Maturi, BL Shirkey, Y Sasamoto, SM Whitcup, I Gery.** In vitro induction of anergy in rat lymphocytes. *J. Cell Biochem.* 18D (Suppl): 446, 1994.
6. **JC Lai, EF Wawrousek, A Fukushima, MC Lobanoff, SM Whitcup, SJ Smith-Gill, I Gery.** Immunotolerance in transgenic mice expressing a foreign antigen in their lens. *Invest Ophthalmol Vis Sci.* 36 (Suppl): 929, 1995. (Oral presentation, 1995 ARVO meeting)
7. **MC Lobanoff, JC Lai, EF Wawrousek, A Fukushima, RS Lee, CC Chan, SM Whitcup, I Gery.** Cell-mediated lens-induced uveitis in transgenic mice: a novel experimental eye disease. *Invest Ophthalmol Vis Sci.* 36 (Suppl). 1995.
8. **A Fukushima, JC Lai, J. Shiloach, Y. Guex-Crosier, SM Whitcup, RB Nussenblatt, I. Gery.** Promiscuous epitopes of human S-antigen stimulate lymphocytes with different MHC restrictions. *Invest Ophthalmol Vis Sci.* 36 (Suppl). 1995.
9. **JC Lai, S Fekrat, Y Barron, MF Goldberg.** Traumatic hyphema in children: risk factors for complications. *Invest Ophthalmol Vis Sci.* 39 (Suppl): 4657, 1998.
10. **JC Lai, P Mruthyunjaya, S Fekrat.** Central retinal vein occlusion in patients on chronic Coumadin anticoagulation. 2002 ARVO meeting.
11. **JC Lai.** Update on Macular Degeneration. Invited speaker at the Annual Connecticut Society of Eye Physicians, 2005.
12. **JC Lai.** Comparison of retrobulbar and sub-tenon's injection of local anesthetic in vitreoretinal surgery. Oral presentation at 2004 Retina Society.

13. BH Zwerling, **JC Lai**, VA Deramo, BJ Rosenblatt. Success of scleral buckle following failed pneumatic retinopexy for repair of rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci. 46 (Suppl). 2005.

Editorial Board

Contemporary Ophthalmology, Assistant Editor, 2002-2003

Organizations

American Academy of Ophthalmology
Association for Research in Vision and Ophthalmology
American Society of Retina Specialists
Wilmer Resident Alumni Association
Duke Resident Alumni Association

Reviewer

Retina
Archives of Ophthalmology

Course Instructor

1. *Controversies in macular hole surgery*. Instructional course at the American Academy of Ophthalmology, Orlando, FL, 2002
2. *Visual outcomes following full macular translocation*. Duke Full Macular Translocation Course, Durham, NC, 2002

Research Protocols

2013 – ongoing	LPath A Phase 2A, Multi-Center, Masked, Randomized Comparator-Controlled Study Evaluating iSONEP™ (Sonepcizumab [LT1009] as Either Monotherapy or Adjunctive Therapy to Lucentis, Avastin or Eylea Versus Lucentis, Avastin or Eylea alone for the treatment of subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration Sub-Investigator
2013 – ongoing	Acucela A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) with Placebo for the Treatment of Geographic Atrophy Associated with Dry Age-Related Macular Degeneration Sub-Investigator
2012 – ongoing	Investigator Sponsored Trial Intravitreal Aflibercept Injection (Eylea) for Polypoidal Choroidal Vasculopathy with Hemorrhage or Exudation (EPIC STUDY) Sub-Investigator

2011 – ongoing	<p>Regeneron Pharmaceuticals A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema Sub-Investigator</p>
2011 – 2011	<p>Allergan A Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX™ (Dexamethasone Intravitreal Implant) 0.7mg injections for Retinal Vein Occlusion Principal Investigator</p>
2010 – ongoing	<p>Investigator Sponsored Trial Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) Sub-Investigator</p>
2009 – 2010	<p>Allergan A 52-week, Masked, Multicentered, Randomized, Controlled Trial (With Up to 13 Weeks Additional Follow-up) to Assess the Safety and Efficacy of 700 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation with Laser Photocoagulation Alone in the Treatment of Subjects with Diffuse Diabetic Macular Edema (DME) Principal Investigator</p>
2009 – 2011	<p>Genentech A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5mg and 2.0mg Ranibizumab Administered Monthly or on an as-needed basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. Sub-Investigator</p>
2008 – 2010	<p>Pfizer Pharmaceuticals A Phase II Prospective, Randomized, Multi-Center, Dose Ranging, comparator Study Evaluating the Efficacy and Safety of PF-04523655 Versus laser in Subjects with Diabetic Macular Edema Sub-Investigator</p>
2008 – 2008	<p>Acuity Pharmaceuticals Phase III, Randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis compared with Lucentis monotherapy every 4 weeks in patients with Exudative Age-Related Macular Degeneration. Sub-Investigator</p>
2008 – 2011	<p>Pfizer Pharmaceuticals A Phase I Open-Label, Dose Escalation Trial of REDD14NP Delivered by a Single Intravitreal Injection to Patients with Choroidal Neovascularization Secondary to Exudative Age-Related Macular Degeneration.</p>

Sub-Investigator

- 2007 – 2010
Novartis Pharmaceuticals
A 24-Month randomized, double-masked, controlled, multicentered, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with ranibizumab (Lucentis™) versus ranibizumab (Lucentis™) monotherapy in patients with subfoveal choroidal Neovascularization secondary to age-related macular degeneration.
Principal Investigator
- 2007 – 2013
Regeneron Pharmaceuticals
A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration
Sub-Investigator
- 2007 – 2010
Allergan
A 52-Week, Masked, Multicenter, Randomized, Controlled Trial (With Up To 13 Weeks Additional Follow-up) to Assess the Safety and Efficacy of 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects With Diffuse Diabetic Macular Edema (DME)
Principal Investigator
- 2007 – 2012
Genentech, Inc
A Phase III, Double Masked, Multicenter, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus – RISE Study
Sub-Investigator
- 2006 – 2007
Regeneron Pharmaceuticals
A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in patients with Neovascular Age-Related Macular Degeneration
Principal Investigator
- 2006 – 2007
Alimera Sciences
A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 mcg/day and ASI-001B 0.2 mcg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema
Sub-Investigator
- 2005 – 2007
Genentech, Inc.
An Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Who Have Completed the Treatment Phase of a Genentech-Sponsored
Ranibizumab Study
Sub-Investigator

- 2005 – 2007
Genentech, Inc.
A Phase IIIb, Multicenter Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Sub-Investigator
- 2004 - 2007
Alcon Research
Posterior Juxtасcleral Administrations of Anecortave Acetate for Depot Suspension versus Sham Administration in Patients at Risk for Developing Sight-Threatening Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration
Sub-Investigator
- 2005 – 2006
Allergan Pharmaceuticals
A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of Dexamethasone Posterior Segment Drug Delivery System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion
Principal Investigator
- 2005 – 2006
Acuity Pharmaceuticals
A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneration
Sub-Investigator
- 2004 - 2006
Genaera Corporation
A Phase 2, Multi-Center, Randomized, Masked, Controlled, Study of Squalamine Lactate for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration
Sub-Investigator
- 2003 - 2006
Genetech, Inc. MARINA Study
rhuFab V2 in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration
Sub-Investigator
- 2003-2006
Genentech, Inc. FOCUS Study
Multiple-dose Intravitreal Injections of rhuFab V2 in Combination with Verteporfin Photodynamic Therapy in Subjects with Neovascular Age-Related Macular Degeneration
Sub-Investigator

- 2003-2006 Eyetech Pharmaceuticals
Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given
Every 6 Weeks for 54 weeks in patients with age-related Macular
Degeneration
Sub-Investigator
- 2003-2005 Alcon Research
Posterior Juxtascleral Injections of Anecortave Acetate versus Visudyne
in Patients with Subfoveal Exudative Age-Related Macular Degeneration
Eligible for Initial Treatment with Photodynamic Therapy using
Visudyne
Sub-Investigator
- 2004-2005 Eyetech Pharmaceuticals
A Phase II Prospective, Randomized, Double-Masked, Sham-Controlled,
Dose-Ranging, Multi-Center Trial to Assess the Effect of Pegaptanib
Sodium on Foveal Thickening in Patients with Exudative Subfoveal Age-
Related Macular Degeneration
Sub-Investigator

Recreational Interests

Racquetball, basketball, baseball, table tennis, and swimming.